| Literature DB >> 29255252 |
Hao Zhang1,2, Long Jiang1, Yu-Jing Yang1, Ren-Kai Ge3, Ming Zhou3, Huan Hu1, Hui Liu1, Jie Cui1, Le-Liang Li1, Yi-Fei Dong1, Xiao-Shu Cheng1, Rong Chen4, Ping Li5.
Abstract
Adropin is a secreted protein that regulates endothelial function. However, adropin levels in obese adolescent patients are currently uncertain. Therefore, we evaluated the association between plasma adropin levels and vascular endothelial function and investigated the effect of aerobic exercise in obese adolescents. A total of 45 obese adolescents and 20 controls (age 16-19 years) were included in our study. The obese adolescents received 12 weeks of aerobic exercise training. Serum adropin was detected using enzyme-linked immunosorbent assay. Vascular reactive hyperemia indexes (RHIs) were obtained using Endo-PAT2000. Adropin levels and RHI were significantly lower in obese adolescents than in normal-weight adolescents. Adropin levels and RHI increased significantly independently of changes in body weight after an exercise intervention (P < 0.01). Pearson correlation analysis revealed that adropin levels positively correlated with HDL-C levels (r = 0.389, P < 0.01) and RHI (r = 0.32, P < 0.01). Multiple linear stepwise regression analysis showed that the insulin resistance index (t = -3.301, P < 0.01) and HDL-C level (t = 2.620, P = 0.011) were independent risk factors of adropin levels. In addition, Δadropin (t = 3.261, P < 0.01) was an independent influencing factor of ΔRHI. Our findings suggest that adropin plays an important role in vascular endothelial function in obese adolescents.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29255252 PMCID: PMC5735148 DOI: 10.1038/s41598-017-18086-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of the obese and control groups.
| Obese Group (n = 45) | Control Group (n = 20) | P value | |
|---|---|---|---|
| Age (years) | 17.9 ± 0.8 | 18.0 ± 0.7 | 0.521 |
| Male (n, %) | 36 (80.0%) | 13 (65.0%) | 0.325 |
| SBP (mmHg) | 128.7 ± 13.6 | 113.7 ± 10.7 | <0.001** |
| DBP (mmHg) | 69.5 ± 7.9 | 61.3 ± 6.5 | <0.001** |
| Height (cm) | 168.3 ± 6.7 | 165.2 ± 9.2 | 0.184 |
| Weight (kg) | 88.9 ± 8.7 | 63.2 ± 11.2 | <0.001** |
| WHR | 0.91 ± 0.04 | 0.84 ± 0.05 | <0.001** |
| BMI (kg/m2) | 31.4 ± 2.7 | 20.4 ± 2.6 | <0.001** |
| Fat mass (kg) | 28.1 ± 6.1 | 13.9 ± 4.5 | <0.001** |
| Total bilirubin (μmol/l) | 12.1 ± 4.6 | 11.4 ± 3.3 | 0.526 |
| AST (μmol/l /l) | 32.4 ± 20.2 | 20.2 ± 7.4 | 0.001** |
| ALT (μmol/l /l) | 22.6 ± 7.6 | 20.5 ± 5.4 | 0.278 |
| BUN (mmol/l) | 4.2 ± 1.0 | 4.3 ± 1.3 | 0.543 |
| Creatinine (μmol/l) | 74.4 ± 11.0 | 71.4 ± 11.0 | 0.299 |
| Uric acid (μmol/l /l) | 438.0 ± 89.7 | 363.6 ± 70.7 | 0.002** |
| TC (mmol/l) | 4.14 ± 0.65 | 4.03 ± 0.69 | 0.562 |
| TG (mmol/l) | 1.33 ± 0.66 | 0.94 ± 0.34 | 0.003** |
| HDL-C (mmol/l) | 1.09 ± 0.18 | 1.28 ± 0.33 | 0.005** |
| LDL-C (mmol/l) | 2.49 ± 0.59 | 2.29 ± 0.58 | 0.198 |
| Glu (mmol/l) | 4.94 ± 0.49 | 4.67 ± 0.47 | 0.042* |
| Fasting insulin (μUI/ml) | 22.0 ± 8.3 | 12.4 ± 6.2 | <0.001** |
| HOMA-IR | 4.8 ± 1.9 | 2.6 ± 1.5 | <0.001** |
| Adropin (ng/ml) | 2.64 ± 0.93 | 3.23 ± 0.87 | 0.018* |
| RHI | 1.70 ± 0.37 | 2.03 ± 0.43 | 0.002** |
| Peak VO2, ml/kg/min | 26.7 ± 1.8 | 32.8 ± 1.4 | < 0.001** |
Note: AST: aspartate aminotransferase; ALT: alanine aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; DBP: diastolic blood pressure; Glu: fasting glucose; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: insulin resistance index; LDL-C: low-density lipoprotein cholesterol; RHI: reactive hyperemia index; SBP: systolic blood pressure; TC: total cholesterol; TG: triglyceride; WHR: waist-to-hip ratio. Data are presented as the means ± standard deviation, *P < 0.05, **P < 0.01.
Figure 1Comparison of the serum adropin concentration and vascular reactive hyperemia index (RHI) between before and after intervention in all subjects. (A) Control group. (B) Obese group before the intervention. (C) Obese group after the intervention. Before the intervention, adropin levels and RHI were lower in the obese group than in the control group. After the intervention, adropin levels and RHI were higher than before the intervention in the obese group.
Comparison of parameters between before and after exercise intervention in the weight loss group.
| Before intervention (n = 37) | After intervention (n = 37) | P value | |
|---|---|---|---|
| Male (n, %) | 33(89.2%) | 33(89.2%) | — |
| Height (cm) | 168.9 ± 6.6 | 169.2 ± 6.7 | 0.024 |
| Weight (kg) | 88.9 ± 9.2 | 83.1 ± 10.4 | <0.001** |
| BMI (kg/m2) | 31.2 ± 2.6 | 29.0 ± 2.9 | <0.001** |
| SBP (mmHg) | 129.1 ± 14.2 | 123.8 ± 12.9 | 0.003** |
| DBP (mmHg) | 69.4 ± 8.0 | 69.9 ± 9.1 | 0.727 |
| Fat mass (kg) | 27.2 ± 5.1 | 19.8 ± 5.0 | <0.001** |
| Total bilirubin (μmol/l) | 12.5 ± 4.8 | 13.6 ± 6.0 | 0.141 |
| AST (μmol/l /l) | 33.9 ± 21.2 | 23.9 ± 22.7 | <0.001** |
| ALT (μmol/l /l) | 22.9 ± 7.8 | 21.4 ± 10.8 | 0.299 |
| BUN (mmol/l) | 4.1 ± 1.0 | 3.7 ± 0.9 | 0.002** |
| Creatinine (μmol/l) | 75.2 ± 11.0 | 72.0 ± 11.6 | 0.001** |
| Uric acid (μmol/l /l) | 440.8 ± 94.2 | 432.0 ± 102.2 | 0.395 |
| TC (mmol/l) | 4.23 ± 0.64 | 3.93 ± 0.58 | <0.001** |
| TG (mmol/l) | 1.30 ± 0.62 | 1.28 ± 0.52 | 0.782 |
| HDL-C (mmol/l) | 1.08 ± 0.18 | 1.26 ± 0.23 | <0.001** |
| LDL-C (mmol/l) | 2.61 ± 0.57 | 2.19 ± 0.44 | <0.001** |
| Glu (mmol/l) | 4.95 ± 0.51 | 4.15 ± 0.48 | <0.001** |
| Fasting insulin (μUI/ml) | 21.6 ± 8.1 | 15.9 ± 7.0 | <0.001** |
| HOMA-IR | 4.8 ± 1.9 | 3.0 ± 1.5 | <0.001** |
| Adropin (ng/ml) | 2.62 ± 0.87 | 3.45 ± 0.65 | <0.001** |
| RHI | 1.71 ± 0.40 | 1.86 ± 0.31 | <0.001** |
| VO2peak,ml/kg/min | 25.8 ± 1.6 | 29.2 ± 1.4 | <0.05* |
Note: AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea nitrogen; DBP: diastolic blood pressure; Glu: fasting glucose; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: insulin resistance index; LDL-C: low-density lipoprotein cholesterol; RHI: reactive hyperemia index; SBP: systolic blood pressure; TC: total cholesterol; TG: triglyceride; data are presented as the means ± standard deviation, *P < 0.05, **P < 0.01.
Figure 2The Pearson correlation analyses of the serum adropin level with TG, HDL-C and insulin levels as well as RHI in all subjects. There was a negative relationship between adropin levels and TG levels, insulin levels, and RHI and a positive relationship between adropin levels and HDL-C levels.
Figure 3The correlation analysis of the change in RHI with the change in serum adropin levels from before to after the exercise intervention in obese adolescents. The results demonstrated that ΔRHI positively correlated with Δadropin.